Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

Crinetics Pharmaceuticals’ (CRNX) shares gained 19.1% on Mar 19 after the company reported positive top-line data from the second (PATHFNDR-2) of two late-stage studies evaluating the efficacy and safety of lead candidate, paltusotine, for the treatment of acromegaly.Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone.The PATHFNDR-2 study is evaluating paltusotine, an oral SST2 agonist, in participants w ...